Dodge & Cox
- SEC CIK
- 0000200217
- Latest filing
- Aug 13, 2026
REGN holding history
Regeneron Pharmaceuticals, Inc. in every 13F filed by Dodge & Cox, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
REGN overviewAll 13F holders of REGNFull Q2 2026 holdings
- Shares (Q2 2026)
- 4,871,137
- Value
- $3.04B
- % of portfolio
- 1.6%
- Quarters held
- 19
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 4,871,137 | $3.04B | 1.6% | +412,899+9.3% | Added | Holders |
| Q1 2026 | 4,458,238 | $3.44B | 1.9% | −138,120−3.0% | Reduced | Holders |
| Q4 2025 | 4,596,358 | $3.55B | 1.9% | +45,513+1.0% | Added | Holders |
| Q3 2025 | 4,550,845 | $2.56B | 1.4% | +724,562+18.9% | Added | Holders |
| Q2 2025 | 3,826,283 | $2.01B | 1.1% | +1,502,198+64.6% | Added | Holders |
| Q1 2025 | 2,324,085 | $1.47B | 0.8% | +2,769+0.1% | Added | Holders |
| Q4 2024 | 2,321,316 | $1.65B | 1.0% | +9,381+0.4% | Added | Holders |
| Q3 2024 | 2,311,935 | $2.43B | 1.4% | −3,751−0.2% | Reduced | Holders |
| Q2 2024 | 2,315,686 | $2.43B | 1.5% | −44,178−1.9% | Reduced | Holders |
| Q1 2024 | 2,359,864 | $2.27B | 1.3% | −7,816−0.3% | Reduced | Holders |
| Q4 2023 | 2,367,680 | $2.08B | 1.3% | −5,318−0.2% | Reduced | Holders |
| Q3 2023 | 2,372,998 | $1.95B | 1.3% | −21,357−0.9% | Reduced | Holders |
| Q2 2023 | 2,394,355 | $1.72B | 1.1% | +9,654+0.4% | Added | Holders |
| Q1 2023 | 2,384,701 | $1.96B | 1.3% | +161,642+7.3% | Added | Holders |
| Q4 2022 | 2,223,059 | $1.60B | 1.1% | −63,450−2.8% | Reduced | Holders |
| Q3 2022 | 2,286,509 | $1.58B | 1.2% | +21,175+0.9% | Added | Holders |
| Q2 2022 | 2,265,334 | $1.34B | 0.9% | +28,271+1.3% | Added | Holders |
| Q1 2022 | 2,237,063 | $1.56B | 0.9% | +1,957,941+701.5% | Added | Holders |
| Q4 2021 | 279,122 | $176.3M | 0.1% | +279,122 | New | Holders |